Evidence

MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience

December 31, 2012

PUBLICATION: Scientifica (Cairo). 2012; 2012: 942507. Published online 2012 Dec 31. doi: 10.6064/2012/942507. AUTHORS: C. Francisco Espinel, Shaughn Keating, Hanina Hibshoosh, Bret Taback, Kathie-Ann Joseph, Mahmoud El-Tamer, and Sheldon Feldman SUMMARY: This study indicates that using MP/TP assay is feasible in a tertiary care center but there may be utility in limiting MP testing to patients with tumors…

Read more

Additional Value of the 70-gene Signature and Levels of ER and PR for the Prediction of Outcome in Tamoxifen-Treated, ER-Positive Breast Cancer

December 1, 2012

PUBLICATION: The Breast. 2012 Dec;21(6):769-78. doi: 10.1016/j.breast.2012.04.010. Epub 2012 Jun 26. AUTHORS: Kok M., Koornstra R.H., Mook S., Hauptmann M., Fles R., Jansen M.P., Berns E.M., Linn S.C., Van ‘t Veer L.J. SUMMARY: In the series analysed, the 70-gene signature was mainly a prognostic factor, while ER and PR levels were mainly associated with outcome after tamoxifen. Combination…

Read more

Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

November 1, 2012

PUBLICATION: Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub 2012 Sep 8. AUTHORS: Lips E.H., Mukhtar R.A., Yau C., de Ronde J.J., Livasy C., Carey L.A., Loo C.E., Vrancken-Peeters M.J., Sonke G.S., Berry D.A., Van’t Veer L.J., Esserman L.J., Wesseling J., Rodenhuis S., Shelley Hwang E.; I-SPY TRIAL Investigators. SUMMARY: Expression subtyping, particularly the NKI 70-gene signature,…

Read more

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

August 15, 2012

PUBLICATION: Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Aug 15. AUTHORS: Nguyen B., Cusumano P.G., Deck K., Kerlin D., Garcia A.A., Barone J..L, Rivera E., Yao K., de Snoo F.A., van den Akker J., Stork-Sloots L., Generali D. SUMMARY: The concordance between BluePrint and IHC/FISH subtyping was 94% for the Luminal-type, 95% for the HER2-type, and…

Read more

Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrint®) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan

June 1, 2012

PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Kondo M., Hoshi S.L., Ishiguro H., Toi M. SUMMARY: The introduction of the assay into Japanese practice of ER+, LN−, HER2− ESBC treatment by including it to Japan’s social health insurance benefit package has a reasonable chance to be judged as cost-effective and may be justified as an…

Read more

Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer: a Decision-Analytic Mode

February 22, 2012

PUBLICATION: Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb 22. AUTHORS: Yang M., Rajan S., Issa A.M. SUMMARY: The model suggested that MammaPrint is a more cost‐effective GEP test compared with Oncotype DX at a threshold willingness‐to‐pay of $50,000 per QALY. Read more: Yang et al_2012_Cancer_Cost Effectiveness of Gene Expression  

Read more

Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance

January 1, 2012

PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub 2011 Sep 24. AUTHORS: Retèl V.P., Joore M.A., van Harten W.H. SUMMARY: The 21-gene has the highest probability of being cost-effective when focusing on cost/LY, while focusing on cost/QALY, the 70-gene signature was most cost-effective. Read more: Breast Cancer Res Treat_Retel et al_The 21-gene has the highest probability…

Read more